TP53 and telomere syndrome: The second trial was a phase I/II study (AMPHISARC, NCT05180695) with two steps (dose-escalation and dose-extension) that analyzes the potential of combining pazopanib with an MDM2 inhibitor (HDM201) in advanced/metastatic STS with p53-wild type.